Several other equities research analysts also recently issued reports on DERM. Zacks Investment Research upgraded Dermira from a “hold” rating to a “buy” rating and set a $8.25 price target for the company in a report on Wednesday, February 13th. HC Wainwright started coverage on Dermira in a report on Thursday, February 14th. They issued a “buy” rating and a $13.00 price target for the company. Svb Leerink started coverage on Dermira in a report on Friday, February 22nd. They issued an “outperform” rating and a $20.00 price target for the company. Leerink Swann started coverage on Dermira in a report on Friday, February 22nd. They issued an “outperform” rating for the company. Finally, ValuEngine upgraded Dermira from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $17.97.
NASDAQ:DERM opened at $9.75 on Thursday. Dermira has a 1-year low of $6.00 and a 1-year high of $15.48. The company has a current ratio of 7.13, a quick ratio of 6.92 and a debt-to-equity ratio of 4.36. The stock has a market capitalization of $540.46 million, a price-to-earnings ratio of -1.86 and a beta of 1.40.
In other Dermira news, insider Eugene A. Bauer sold 35,000 shares of the stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $15.00, for a total value of $525,000.00. Following the completion of the sale, the insider now directly owns 43,900 shares in the company, valued at $658,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.80% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the business. Fifth Third Bancorp bought a new position in shares of Dermira during the first quarter worth about $44,000. Advisor Group Inc. grew its holdings in shares of Dermira by 117.0% during the first quarter. Advisor Group Inc. now owns 6,062 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 3,269 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its holdings in shares of Dermira by 356.7% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 12,912 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 10,085 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Dermira during the fourth quarter worth about $95,000. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of Dermira by 48,273.3% during the first quarter. BNP Paribas Arbitrage SA now owns 7,256 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 7,241 shares in the last quarter. Institutional investors own 93.92% of the company’s stock.
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Further Reading: Why do companies engage in swaps?
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.